Oct. 29, 2020—Randox Laboratories has unveiled its Qnostics Multiplex Respiratory Pathogen Controls for respiratory diseases, including for SARS-CoV-2, influenza A and B, and respiratory syncytial virus. The RTX controls are used to monitor the full testing process, from extraction to amplification and detection, and are compatible with a majority of commercial and in-house assays.
“Accurate and reliable laboratory testing is an essential aspect of the management of COVID-19 and other respiratory diseases, so we are pleased to be able to offer these new controls, which will crucially support the validation, verification, and performance monitoring of molecular respiratory assays,” Lynsey Adams, Randox quality control manager, said in a press release.
Qnostics controls are quantified by digital PCR to ensure batch-to-batch reproducibility and are traceable to an internal reference preparation. They are manufactured to ISO 13485 standards and are in line with ISO 15189:2012 regulatory requirements.